AU2185592A - Induction of ctl responses to foreign antigens expressed in mycobacteria - Google Patents
Induction of ctl responses to foreign antigens expressed in mycobacteriaInfo
- Publication number
- AU2185592A AU2185592A AU21855/92A AU2185592A AU2185592A AU 2185592 A AU2185592 A AU 2185592A AU 21855/92 A AU21855/92 A AU 21855/92A AU 2185592 A AU2185592 A AU 2185592A AU 2185592 A AU2185592 A AU 2185592A
- Authority
- AU
- Australia
- Prior art keywords
- fragment
- dna
- protein
- bcg
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004044 response Effects 0.000 title claims description 18
- 239000000427 antigen Substances 0.000 title description 45
- 108091007433 antigens Proteins 0.000 title description 45
- 102000036639 antigens Human genes 0.000 title description 44
- 230000006698 induction Effects 0.000 title description 5
- 239000012634 fragment Substances 0.000 claims description 111
- 108090000623 proteins and genes Proteins 0.000 claims description 92
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 50
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 94
- 108020004414 DNA Proteins 0.000 description 74
- 238000003752 polymerase chain reaction Methods 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 36
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 238000010276 construction Methods 0.000 description 35
- 230000010076 replication Effects 0.000 description 31
- 230000010354 integration Effects 0.000 description 30
- 239000013615 primer Substances 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 22
- 101000607560 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 3 Proteins 0.000 description 22
- 108010061833 Integrases Proteins 0.000 description 22
- 102100039936 Ubiquitin-conjugating enzyme E2 variant 3 Human genes 0.000 description 22
- 241000187480 Mycobacterium smegmatis Species 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 102000006303 Chaperonin 60 Human genes 0.000 description 20
- 108010058432 Chaperonin 60 Proteins 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 18
- 241000186359 Mycobacterium Species 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 15
- 108010005774 beta-Galactosidase Proteins 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 239000003550 marker Substances 0.000 description 13
- 108020004705 Codon Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000013604 expression vector Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 229960000318 kanamycin Drugs 0.000 description 11
- 208000031886 HIV Infections Diseases 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 8
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 8
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000009089 cytolysis Effects 0.000 description 8
- 238000002703 mutagenesis Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 241001515965 unidentified phage Species 0.000 description 7
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 101150023414 HSP60 gene Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- -1 but not limited to Proteins 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000002516 postimmunization Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 244000026610 Cynodon dactylon var. affinis Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241001131785 Escherichia coli HB101 Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241001429274 Mycobacterium virus L5 Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000725643 Respiratory syncytial virus Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 101150057950 aph gene Proteins 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 101150062334 int gene Proteins 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000012809 post-inoculation Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001244729 Apalis Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000186364 Mycobacterium intracellulare Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 2
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 2
- 241000713124 Rift Valley fever virus Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 238000012808 pre-inoculation Methods 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 210000003046 sporozoite Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 101710168628 45 kDa antigen Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108020005075 5S Ribosomal RNA Proteins 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 101100327692 Caenorhabditis elegans hsp-60 gene Proteins 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000239183 Filaria Species 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 1
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 108700020123 Human Immunodeficiency Virus-2 rev Proteins 0.000 description 1
- 108700020147 Human immunodeficiency virus 1 vif Proteins 0.000 description 1
- 108700018662 Human immunodeficiency virus 1 vpr Proteins 0.000 description 1
- 108700020148 Human immunodeficiency virus 2 vif Proteins 0.000 description 1
- 108700018663 Human immunodeficiency virus 2 vpr Proteins 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 102100024407 Jouberin Human genes 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241001147830 Mycobacterium lufu Species 0.000 description 1
- 241000187481 Mycobacterium phlei Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229930183781 Mycobactin Natural products 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 241001439627 Schistostoma Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 241000589886 Treponema Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003936 merozoite Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XZGYBQIQSLSHDH-COEJQBHMSA-N mycobactin Chemical compound C1CCCN(O)C(=O)C1NC(=O)C(C)C(CC)OC(=O)C(CCCCN(O)C(=O)\C=C/CCCCCCCCCCCCCCC)NC(=O)C(N=1)COC=1C1=C(C)C=CC=C1O XZGYBQIQSLSHDH-COEJQBHMSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 101150118377 tet gene Proteins 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
INDUCTION OF CTL RESPONSES TO FOREIGN
ANTIGENS EXPRESSED IN MYCOBACTERIA
This invention relates to the induction of a T-cell
response, in particular a cytotoxic T lymphocyte response. More particularly, this invention relates to the induction of CTL responses to proteins or polypeptides expressed by recombinant mycobacteria.
Cell-mediated immunity (or CMI ) of infections is thought to be a major line of defense against certain infections, such as viral infections and certain bacterial infections. For example, CMI may be significant in the development of an effective vaccine against human immunodeficiency virus (HIV), or AIDS virus, because HIV vaccines and/or therapies based on the generation of passive transfer of HIV-specific antibody in the absence of eel L-mediated immunity have not yielded consistent protection in primates challenged with the HIV virus. Thus, interest has turned to the induction of cell-mediated responses to various infections, such as for example, HIV infection, and to the identification of proteins or polypeptides that a stimulate a cytotoxic T lymphocyte response, and to methods of administering such proteins or polypeptides.
In accordance with an aspect of the present invention, there is provided a method of inducing a CTL response in an animal comprising administering to the animal mycobacteria transformed with at least one DNA sequence which encodes a protein or peptide or fragment or derivative thereof which includes an epitope which
is recognized by cytotoxic T lymphocytes. The mycobacteria are administered in an amount effective to induce a CTL response in an animal.
Proteins or polypeptides for which the at least one DNA sequence may encode, include, but are not limited to,
Mycobacterium leprae antigens; Mycobacterium tuberculosis
antigens; Rickettsia antigens; Chlamydia antigens; Coxiella antigens; malaria sporozoite and merozoite proteins, such as the circumsporozoite protein from Plasmodium berghei sporozoites; Clostridium antigens; Leishmania antigens; Salmonella antigens; Mycobacterium africanum antigens; Mycobacterium intracellulare antigens; Mycobacterium avium antigens; E.coli antigens; Borrelia antigens; Listeria antigens; Franciscella antigens; Yersinia antigens; Treponema antigens; Schistostoma antigens; Filaria antigens; Pneumococcus antigens; Staphylococcus antigens; Herpes virus antigens; influenza and parainfluenza virus antigens;
measles virus antigens; mumps virus antigens; hepatitis virus antigens; Shigella antigens; Bordatella antigens; Hemophilus antigens; Streptococcus antigens; polio virus antigens; Rift Valley Fever virus antigens; dengue virus antigens; Human
Immunodeficiency Virus (HIV) antigens; and respiratory syncytial virus (RSV) antigens.
In one embodiment, the at least one DNA sequence encodes at least one protein or polypeptide or fragment or derivative thereof which includes an eptiope which is recognized by
cytotoxic T lymphocytes induced by an HIV protein or fragment or derivative thereof. The at least one DNA sequence may encode an HIV protein or fragment or derivative thereof. HIV proteins or polypeptides which may be encoded by the at least one DNA
sequence includes but are not limited to, HIV-I-gp 120; HIV-I-gp 41; HIV-I-gp 160; HIV-I-pol; HIV-I-nef; HIV-I-tat; HIV-I-rev;
HIV-I-vif; HIV-I-vpr; HIV-I-vpu; HIV-I-gag; HIV-2-gp 120;
HIV-2-gp 160; HIV-2-gp 41; HIV-2-gag; HIV-2-pol; HIV-2-nef;
HIV-2-tat; HIV-2-rev; HIV-2-vif; HIV-2-vpr; HIV-2-vpu; and
HIV-2-vpx.
Mycobacteria which may be transformed with the at least one DNA sequence, which encodes a protein or polypeptide or fragment or derivative thereof which includes an epitope which is
recognized by cytotoxic T lymphocytes, include, but are not limited to, Mycobacterium bovis-BCG, M. smegmatis, M. avium,
M.phlei, M.fortiutum, M. lufu, M.paratuberculosis, M.habana,
M. scrofalaceum, and M. intracellulare. In a preferred embodiment the mycobacterium is M.bovis-BCG or a mutant thereof.
The at least one DNA sequence may be contained within an expression vector, which is transformed into a mycobacterium, whereby the mycobacterium expresses the protein or polypeptide or fragment or derivative thereof which includes an epitope which is recognized by cytotoxic T lymphocytes.
The expression vector may be, for example, a temperate shuttle phasmid or a bacterial-mycobacterial shuttle plasmid. Each of these vectors may be used to introduce the at least one DNA sequence encoding a protein or polypeptide or fragment or derivative which includes an epitope which is recognized by cytotoxic T lymphocytes, stably into mycobacteria, in which the at least one DNA sequence may be expressed. When a shuttle phasmid, which replicates as a plasmid in bacteria and a phage in mycobactreia, is employed, integration of the phasmid, which includes the at least one DNA sequence encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes, into the mycobactarial chromosome occurs through site-specific
integration. The at least one DNA sequence which encodes a protein or polypeptide or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic
T lymphocytes, is replicated as part of the chromosomal DNA. When a bacterial-mycobacterial shuttle plasmid is employed, the at least one DNA sequence which encodes a protein or polypeptide or
fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes, is stably maintained extrachromosomally in a plasmid. Expression of the at least one DNA sequence occurs extrachromosomally (e.g., episomally). For example, the at least one DNA sequence is cloned into a shuttle plasmid and the plasmid is introduced into a mycobacterium such as those hereinabove described, wherein the plasmid replicates episomally. Examples of such shuttle phasmids and
bacterial-mycobacterial shuttle plasmids are further described in Application Serial No. 361,944, filed June 5, 1989, which is hereby incorporated by reference.
In one embodiment the mycobacteria are transformed with an expression vector which comprises at least one DNA sequence encoding a protein or polypeptide which includes an epitope which is recognized by cytotoxic T lymphocytes, and a promoter selected from the class consisting of mycobacterial promoters and
mycobacteriophage promoters for controlling expression of the DNA encoding the heterologous protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes.
Mycobacterial and mycobacteriophage promoters which may be employed include, but are not limited to, mycobacterial promoters such as the BCG HSP60 and HSP70 promoters; the mycobactin
promoter from M. tuberculosis and BCG; the mycobacterial 14 kda and 12 kda antigen promoters; the mycobacterial α-antigen
promoter from M. tuberculosis or BCG; the MBP-70 promoter, the mycobacterial 45 kda antigen promoter from M. tuberculosis or BCG; the supβroxide dismutase promoter; the mycobacterial asd
promoter, and mycobacteriophage promoters such as the Bxbl, L1, L5, and TM4 promoters. In one embodiment, the promoter is a mycobacterial heat shock protein promoter such as HSP60 or HSP70.
The promoter sequence may, in one embodiment, be part of an expression cassette which also includes a portion of the gene normally under the control of the promoter. For example, when a
mycobacterial HSP60 or HSP70 promoter is employed, the expression cassette may, within the scope of the present invention, include, in addition to the promoter, a portion of the gene for the HSP60 or HSP70 protein. When the expression cassette and the DNA encoding the protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by
cytotoxic T lymphocytes are expressed, the protein expressed by the cassette and the DNA encoding the protein or polypeptide is a fusion protein of a fragment of a mycobacterial protein (eg., the HSP60 or HSP70 protein), and the protein or polypeptide or fragment or deriviative thereof which includes an epitope which is recognized by cytotoxic T lymphocytes.
In a preferred embodiment, the transcription initiation site, the ribosomal binding site, and the start codon, which provides for the initiation of the translation of mRNA, are each of mycobacterial origin. The stop codon, which stops translation of mRNA, thereby terminating synthesis of the protein or
polypeptide or fragment or derivative thereof which includes an epitope which is recognized by cytotoxic T lymphocytes, and the transcription termination site, may be of mycobacterial origin, or of other bacterial origin, or such stop codon and
transcription termination site may be those of the DNA encoding the protein or polypeptide which includes an epitope which is recognized by cytotoxic T lymphocytes.
Preferably, the mycobacterial promoter is a BCG promoter, and the mycobacterium is BCG.
In one embodiment, the expression vector may further include DNA which encodes for proteins or polypeptides such as, but not limited to, antigens, anti-tumor agents, enzymes, lymphokines, pharmacologic agents, immunopotentiators, reporter molecules of interest in a diagnostic context, and selectable markers.
Selectable markers which may be encoded include, but are not limited to, the β-galactosidase marker, the kanamycin resistance
marker, the chloroamphenicol resistance marker, the neomycin resistance marker, and the hygromycin resistance marker.
In accordance with one embodiment, the vector further includes a mycobacterial origin of replication.
In accordance with another embodiment, the vector may be a plasmid. The plasmid may be a non-shuttle plasmid, or may be a shuttle plasmid which further includes a bacterial origin of replication such as an E.coli origin of replication, a Bacillus origin of replication, a Staphylococcus origin of replication, a Streptomyces origin of replication, or a pneumococcal origin of replication. In one embodiment, the shuttle plasmid includes an E. coli origin of replication.
In accordance with yet another embodiment, the vector may further include a multiple cloning site, and the DNA encoding for the protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic
T lymphocytes is inserted in the multiple cloning site.
In addition to the DNA encoding a heterlogous protein or polypeptide, and the mycobacterial promoter for controlling expression of the DNA encoding the protein or polypeptide which includes an epitope which is recognized by cytotoxic
T lymphocytes, the expression vector may, in one embodiment, further include a DNA sequence encoding bacteriophage integration into a mycobacterium chromosome. Bacteriophages from which the DNA sequence encoding bacteriophage integration into a
mycobacterium chromosome may be derived include, but are not limited to, mycobacteriophages such as but not limited to, the L5, L1, Bxbl, and TM4 mycobacteriophages; the lambda phage of E. coli; the toxin phages of Corynebacteria; phages of Actinomycetes and Norcardia; the ΦC31 phage of Streptomvces; and the P22 phage of Salmonella. Preferably, the DNA sequence encodes
mycobacteriophage integration into a mycobacterium chromosome. The DNA sequence which encodes bacteriophage integration into a mycobacterium chromosome may include DNA which encodes integrase,
which is a protein that provides for integration of the vector into the mycobacterial chromosome. Preferably, the DNA sequence encoding mycobacterial phage integration also includes DNA which encodes an attP site.
The DNA encoding the attP site and the integrase provides for an integration event which is referred to as site-specific integration. DNA containing the attP site and the integrase gene is capable of integrating into a corresponding attB site of a mycobacterium chromosome.
It is to be understood that the exact DNA sequence encoding the attP site may vary among different phages, and that the exact DNA sequence encoding the attB site may vary among different mycobacteria.
Examples of expression vectors which include mycobacterial promoters and mycobacteriophage promoters, for controlling the at least one DNA sequence encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes are further described in application Serial No. 642,017, filed January 16, 1991, which is a continuation of Application Serial No. 552,828, filed July 16, 1990, now abandoned. The contents of Application Serial No.
642,017 are hereby incorporated by reference.
In another embodiment, the mycobacteria are transformed with DNA which comprises a first DNA sequence which is a phage DNA portion encoding bacteriophage integration into a mycobacterium chromosome, and DNA including the at least one DNA sequence encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by
cytotoxic T lymphocytes.
The term "phage DNA portion", as used herein, means that the DNA sequence is derived from a phage and lacks the DNA which is required for phage replication.
Bacteriophages from which the phage DNA portion may be derived include, but are not limited to, mycobacteriophages, such
as but not limited to the those hereinabove described.
Preferably, the phage DNA portion encodes mycobacteriophage integration into a mycobacterium chromosome.
In a preferred embodiment, the first DNA sequence includes
DNA encoding integrase, which is a protein that provides for integration of the DNA into the mycobacterial chromosome. Most preferably, the first DNA sequence also includes DNA which encodes an AttP site.
The DNA sequence encoding the AttP site and the integrase provides for an integration event which is referred to as site-specific integration. DNA containing the AttP site and the integrase gene is capable of integration into a corresponding AttB site of a mycobacterium chromosome.
It is to be understood that the exact DNA sequence encoding the attP site may vary among different phages, and that the exact DNA sequence encoding the attB site may vary among different mycobacteria.
The integration event results in the formation of two new junction sites called AttL and AttR, each of which contain part of each .of AttP and AttB. The inserted and integrated non-phage DNA which includes the first DNA sequence and the at least one DNA sequence, which encodes a protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is
recognized by cytotoxic T lymphocytes is flanked by the AttL and AttR sites. The insertion and integration of the phage DNA portion results in the formation of a transformed mycobacterium.
The DNA may further include DNA which encodes a selectable marker or markers; or other proteins or polypeptides of interest, such as, but not limited to anti-tumor agents, enzymes,
lymphokines, pharmacologic agents, immunopotentiators, and reporter molecules of interest in a diagnostic context.
Selectable markers which may be encoded include, but are not limited to, the kanamycin resistance marker, the neomycin
resistance marker, the chloroamphenicol resistance marker, and the hygromycin resistance marker.
The phage DNA portion of the present invention, which includes the first DNA sequence encoding mycobacterium phage integration into a mycobacterium chromosome, and the at least on DNA sequence encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope recognized by cytotoxic T lymphocytes, may be constructed through genetic engineering techniques known to those skilled in the art. In a preferred embodiment, the phage DNA portion may be a plasmid including, in addition to the DNA encoding integration and the DNA encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope recognized by cytotoxic
T lymphocytes, an origin of replication for any of a wide variet of organisms, which includes, but is not limited to, E.coli,
Streptomyces species, Bacillus species, Staphylococcus species, Shigella species, Salmonella species and various species of pneumococci. Most preferably, the plasmid includes an origin of replication for E.coli.
The phage DNA portion also may include a suitable promoter. Suitable promoters include, but are not limited to, mycobacterial promoters and mycobacteriophage promoters such as those
hereinabove described.
The promoter sequence may, in one embodiment, be part of an expression cassette which also includes a portion of the gene normally under the control of the promoter, as hereinabove described. For example, when a mycobacterial HSP60 or HSP70 promoter is employed, the expression cassette may include, in addition to the promoter, a portion of the gene for the HSP60 or HSP70 protein. When the expression cassette and the DNA encodin the protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes are expressed, the protein expressed by the cassette and the DNA encoding the protein or polypeptide is a fusion
protein of a fragment of a mycobacterial protein (eg., the HSP60 or HSP70 protein), and the protein or polypeptide, or fragment or erivaitve thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes.
In a preferred embodiment, the transcription initiation s e, the ribosomal binding site, and the start codon, which provides for the initiation of the translation of mRNA, are each of mycobacterial origin. The stop codon, which stops translation of mRNA, thereby terminating synthesis of the protein or
polypeptide, or fragment or deriviatve thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes, and the transcription termination site, may be of mycobacterial origin, or of other bacterial origin, or such stop codon and
transcription termination site may be those of the DNA encoding the protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic
T lymphocytes.
Examples of DNA which includes a first DNA sequence which is a phage DNA portion encoding bacteriophage integration into a mycobacterium chromosome, and DNA including the at least one DNA sequence encoding a protein or polypeptide, or fragment or derivative thereof, which includes an epitope which is recognized by cytotoxic T lymphocytes are further described in application Serial No. 553,907, filed July 16, 1990, the contents of which are hereby incorporated by reference.
Mycobacteria which are transformed which DNA which encodes for a protein or polypeptide or fragment(s) or derivative(s) thereof, which includes an epitope which is recognized by
cytotoxic T lymphocytes, may be employed in a composition, such as a vaccine, for inducing a CTL response in an aniaml. The vaccine may be administered to a human or non-human animal.
To form such a vaccine, the transformed mycobacteria are administered in conjunction with a suitable pharmaceutical
carrier. As representative examples of suitable carriers there
may be mentioned: mineral oil, alum, synthetic polymers, etc. Vehicles for vaccines are well known in the art and the selection of a suitable vehicle is deemed to be within the scope of those skilled in the art from the teachings contained herein. The selection of a suitable vehicle is also dependent upon the manner in which the vaccine is to be administered. The vaccine may be in the form of an injectable dose and may be administered
intramuscularly, intravenously, orally, intradermally, or by subcutaneous administration.
Other means for administering the vaccine or therapeutic agent should be apparent to those skilled in the art from the teachings herein; accordingly, the scope of the invention is not to be limited to a particular delivery form.
When the transformed mycobacteria are employed as a vaccine, such a vaccine has important advantages over other presently available vaccines. Mycobacteria have, as hereinabove indicated, adjuvant properties among the best currently known and,
therefore, stimulate a recipient's immune system to respond with great effectiveness. This aspect of the vaccine induces
cell-mediated immunity and thus is especially useful in providing immunity against pathogens in cases where cell-mediated immunity appears to be critical for resistance. Also, mycobacteria may stimulate long-term memory or immunity. It thus may be possible to prime long-lasting T cell memory, which stimulates secondary antibody responses neutralizing to the infectious agent. Such priming of T cell memory is useful, for example, against
pertussis, malaria, influenza virus, Herpes virus, rabies, Rift Valley fever virus, dengue virus, measles virus, Human
Immunodeficiency Virus (HIV), and respiratory syncytial virus.
The invention will now be described with respect to the following examples; however, the scope of the present invention is not to be limited thereby.
Example 1
A. Construction of plasmid including mycobacterial promoter expression cassette and lacZ gene.
1. Construction of PYUB125
Plasmid pAL5000, a plasmid which contains an origin of replication of M. fortuitum, and described in Labidi, et al., FEMS Microbiol. Lett., Vol. 30, pgs. 221-225 (1985) and in Gene, Vol. 71, pgs. 315-321 (1988), is subjected to a partial Sau 3A digest, and 5kb fragments are gel purified. A 5kb fragment is then ligated to Bam HI digested pIJ666 (an. E. coli vector containing an E. coli origin of replication and also carries neomycin-kanamycin resistance, as described in Kieser, et al., Gene, Vol. 65, pgs. 83-91 (1988) to form plasmid pYUB12. A schematic of the formation of plasmid pYUB12. A schematic of the formation of plasmid pYUB12 is shown in Figure 1. pYUB12 and pIJ666 were then transformed into M. smegmatis and BCG.
Neomycin-resistant transformants that were only obtained by pYUB12 transformation confirmed that pAL5000 conferred autonomous replication to pIJ666 in M. smegmatis and BCG.
Shotgun mutagenesis by Snapper, et al (1988, hereinabove cited) indicated that no more than half of the pAL5000 plasmid was necessary to support plasmid replication in BCG. This segment presumably carried open reading frames ORF1 and ORF2, identified by Rauzier, et al., Gene, Vol. 71, pgs. 315-321
(1988), and also presumably carried a mycobacterial origin of replication. pYUB12 is then digested with Hpal and EcoRV, a 2586 bp carrying this region or segment pAL5000 is removed and ligated to PvuII digested pYUB8. Plasmid pYUB8 (a pBR322 derivative) includes an E. coli replicon and a kan (aph) gene. Ligaticn of the 2586 bp pYUB12 fragment to PvuII digested pYUB8 results in the formation of pYUB53, as depicted in Figure 2. Transformation of pYUB53 confirmed that the EcoRV-HpaI fragment, designated M.rep, was capable of supporting autonomous replication in BCG.
Plasmid pYUB53 was then digested with AatI, EcoRV, and PstI in order to remove the following restriction sites:
AatI 5707
EcoRI 5783
BamHI 5791
Sail 5797
PstI 5803
PstI 7252
Sail 7258
BamHI 7264
EcoRI 7273
Clal 7298
HindIII 7304; and
EcoRV 7460
Fragment ends are then flushed with T4 DNA polymerase and religated to form plasmid pYUB125, construction of which is show in Figure 3.
2. Elimination of superfluous vector DNA from pYUB125
792 bases of the tet gene, which had been inactivated by prior manipulations, was eliminated by a complete NarI digest, gel purification of the 6407 bp fragment, and
ligation/recirculation, transformation of E. coli strain HB101, and selection of KanR transformants. The construction of
resulting plasmid, pMV101, is schematically indicated in Figure 4, and the DNA sequence of pMV101, which includes markings of regions which will be deleted, and of mutations, as hereinafter described, is shown in Figure 5.
3. Construction of expression cassette based on BCG HSP60. Among the most abundant proteins in mycobacteria is the
HSP60 heat shock protein (also known as the 65 kda antigen).
Because abundance of the HSP60 protein in mycobacteria indicates strong HSP60 gene expression, the sequence controlling HSP60 expression was chosen to control expression of heterologous gene encoding antigens or other proteins in BCG.
The published sequence of the BCG HSP60 gene (Thole, et al, Infect, and Immun., Vol. 55, pgs. 1466-1475 (June 1987)), and
surrounding sequence permitted the construction of a cassette carrying expression control sequences (i.e., promoter and translation initiation sequences) by PCR. The BCG HSP61 cassette (Figure 6) contains 375 bases 5' to the BCG HSP60 start codon, and 15 bases (5 codons) 3' to the start codon. PCR
oligonucleotide primers were then synthesized. Primer Xba-HSP60, of the following sequence:
CAG ATC TAG ACG GTG ACC ACA ACG CGC C /
was synthesized for the 5' end of the cassette, and primer
Bam-HSP61, of the following sequence:
CTA GGG ATC CGC AAT TGT CTT GGC CAT TG α
was synthesized for the 3' end of the cassette. The primers were used to amplify the cassette by PCR from BCG strain Pasteur chromosomal DNA. The addition of the Bam HI site at the 3' end of the cassette adds one codon (Asp) to the first six codons of the HSP60 gene.
Each of pMV101 and the PCR cassette HSP61 was digested with Nhel and BamHI. The PCR cassette was then inserted between the Nhel and BamHI sites of pMV101, then ligated to form plasmid pMV65A (Figure 7).
The E. coli lac 2 gene (Figure 8) was used as a reporter, or marker gene to assay the ability of the HSP61 cassette to express heterologous genes in BCG. A BamHI restriction fragment carrying the lac Z gene was cloned into the Bam HI site of Bam HI digested pMV65A, resulting in the formation of pMV65A/LZ as indicated schematically in Figure 7. The formation of pMV65A/LZ results in a fusion between the HSP60 and lac Z genes at the sixth codon of the HSP60 gene and the sixth codon of the lac Z gene. pMV65A/LZ was then transformed into E. coli. Blue E. coli colonies were selected on x-gal plates for the presence of pMV65A/LZ, thus indicating that the HSP60 promoter and translation initiation sequences were also active in E. coli.
pMV65A/LZ was then transformed into BCG and plated on Dubos Oleic Agar plates containing x-gal. All BCG colonies resulting
from this transformation exhibited blue color, thus indicating that the lac Z gene product (B-galactosidase) was expressed in BCG. SDS polyacrylamide gel electrophoresis was performed on lysates of the pMV65A/LZ BCG recombinants, revealing that
B-galactosidase protein was expressed to levels in excess of 10 of total BCG protein (as determined by staining with Coomassie brilliant blue). These data indicated that BCG HSP61 expressio cassette was functional in expression vector pMV65A.
Example 2
Cytotoxic T lymphocyte response to E. coli B-galactosidase.
E. coli B-galactosidase was expressed in BCG as a six amino acid fusion protein with BCG hsp 60 protein using
extrachromosomal plasmid vector pMV65A/LZ utilizing the HSP60 promoter to drive expression. The recombinant BCG was grown to mid-log phase in Dubos media and concentrated by centrifugation The bacteria were then re-suspended in PBS plus 0.05% Tween 80 and cup sonicated briefly to disperse clumped bacteria. Six we old BALB/c mice were inoculated with a single dose of 2 × 102, 2 × 10 , or 2 × 10 colony forming units (CFU'S determined post-inoculation) by either intradermal (ID), intraperitoneal (IP), or intravenous (IV) injection. At 14 or 19 weeks
post-immunization splenocytes were harvested from mice and CTL activity was measured. CTL activity was measured as follows:
Splenocytes (ACK-treated, 5 × 10 /ml) were stimulated in vitro in 10 ml in upright T25 flasks by co-culture for 5 days with mitomycin C-treated cells transfected with the lac Z gene (C3-4 cells; 5 × 106/ml). A 4 hr. 51Cr release assay was then performed in triplicate using P815 and P13.1 cells (P815 ceils transfected with the lac Z gene) as targets. Various
effector-target ratios were tested using 5,000 targets/well.
Specific lysis was calculated as follows: % specific lysis = 100 × [release by effector cells minus spontaneous release/ maximal release minus spontaneous release].
At 19 weeks post-immunization, the remaining animals in each group were boosted by intraperitoneal injection at 10 μg of purified lac Z emulsified in incomplete Freund's adjuvant (IFA). Splenocytes were then harvested from these animals at 23 weeks and CTL ctivity was again measured. Unimmunized animals or animals mmunized with lac Z emulsified in IFA, or animals immunized with vaccinia virus expressing lac Z served as
controls.
The results of the avove experiments, as determined by % specific lysis of target cells, indicated that a CTL response was induced in mice immunized with BCG transformed with the
expression vector pMV65A/LZ.
Example 3
Construction of integrating plasmid including mycobacterial promoter expression cassette and HIV-I-gp 120 gene.
1. Elimination of undesirable restriction sites in aph (kanR). gene.
To facilitate future manipulations, the HindIII and ClaI restriction sites in the aph gene in plasmid pMV101 were
mutagenized simultaneously by polymerase chain reaction (PCR) mutagenesis according to the procedure described in Gene, Vol. 77 pgs. 57-59 (1989). The bases changed in the aph gene were at the third position of codons (wobble bases) within each restriction site and the base substitutions made were designed not to change the amino acid sequence of the encoded protein.
Separate PCR reactions of plasmid pMV101 with primer
ClaMut-Kan + HindRMut-Kan and HindFMut-Kan + Barn-Kan were
performed at 90°C (1 min.), 50°C (1 min.), and 72°C (1 min.) for 25 cycles. The PCR primers had the following base seqeuences:
ClaMut-Kan
CTT GTA TGG GAA GCC CC 3
HindRMut-Kan
GTG AGA ATG GCA AAA GAT TAT GCA TTT CTT TCC AG 4
HindFMut-Kan
GTG TGG AAA GAA ATG CAT AAT CTT TTG CCA TTC TCA CCG G 5
Bam-Kan
CGT AGA GGA TCC AGA GGA CG 6
The resulting PCR products were gel purified and mixed and a single PCR reaction without primers was performed at 94°C (1 min.), 72°C (1 min.) for 10 cycles. Primers ClaMut-Kan and
Bam-Kan were added and PCR was resumed at 94°C (1 min.), 50°C ( 1 min . ) , and 72 °C ( 2 min . ) for 20 cylces . The resulting PCR product (Kan. mut) was digested with BamHI and gel purified.
Plasmid pMV101 was digested with Clal and cohesive ends were filled in by Klenow + dCTP + dGTP. Klenow was heat inactivated and the digest was further digested with BamHI. The 5232 base pair fragment was gel purified and mixed with fragment Kan.mut and ligated. The ligation was transformed into E. coli strain HB101 and KanR colonies were screened for plasmids resistant to
Clal and HindIII digestion. Such plasmids were designated as pMV110, which is depicted in Figure 4.
2. Elimination of sequences not necessary for plasmid replication in mycobacteria.
Plasmid pMV110 was resected in separate constructions to yield plasmids pMV111 and pMV112. In one construction, pMV110 was digested with Narl and Ball, the ends were filled in, and a 5296 base pair fragment was ligated and recircularized to form pMV111. In another construct, pMV110 was digested with Ndel and SplI, the ends were filled in, and a 5763 base pair fragment was ligated and recircularized to form pMV112. Schematics of the constructions of pMV111 and pMV112 are shown in Figure 9. These constructions further eliminated superfluous E. coli vector sequences derived from pAL5000 not necessary for mycobacterial replication. Cloning was performed in E. coli. Plasmids pMV111 and pMV112 were tested for the ability to replicate in M .
smegmatis. Because both plasmids replicated in M. smegmatis the deletions of each plasmid were combined to construct pMV113.
(Figure 9).
To construct pMV113, pMVlll was digested with BamHI and EcoRI, and a 1071 bp fragment was isolated. pMV112 was digested with BamHI and EcoRI, and a 3570 bp fragment was isolated, and then ligated to the 1071 bp fragment obtained from pMVlll to form pMV113. These constructions thus defined the region of pAL5000 necessary for autonomous replication in mycobacteria as no larger than 1910 base pairs.
3.. Mutagenesis of restriction sites in mycobacterial replicon.
To facilitate further manipulations of the mycobacterial replicon, PCR mutagenesis was performed as above to eliminate the Sal I, EcoRI, and BglII sites located in the open reading frame known as ORFl of pAL5000. PCR mutagenesis was performed at wobble bases within each restriction site and the base
substitutions were designed not to change the amino acid sequence of the putative encoded ORFl protein. The restriction sites were eliminated one at a time for testing in mycobacteria. It was possible to eliminate the Sail and EcoRI without altering
replication in M. smegmatis. In one construction PCR mutagenesis was performed at EcoRI1071 of pMV113 with primers Eco Mut - M.rep and Bam-M.rep to form pMV117, which lacks the EcoRI1071 site.
Primer Eco Mut - M.rep has the following sequence:
TCC GTG CAA CGA GTG TCC CGG A; 7
and Bam-M.rep has the following sequence:
CAC CCG TCC TGT GGA TCC TCT AC. 8
In another construction, PCR mutagenesis was performed at the Sail 1389 site with primer Sal Mut - M.rep and Bam-M.rep to form pMV119, which lacks the Sail 1389 site. Primer Sal Mut-M.rep has the following sequence:
TGG CGA CCG CAG TTA CTC AGG CCT. 9
pMV117 was then digested with ApaLI and Bglll, and a 3360 bp fragment was isolated. pMV119 was digested with ApaLI and BglII, and a 1281 bp fragment was isolated and ligated to the 3360 bp fragment isolated from pMV117 to form pMV123. A schematic of the
constructions of plasmids pMV117, pMV119, and pMV123 is shown in Figure 10. Elimination of the Bglll site, however, either by PCR mutagenesis or Klenow fill in, eliminated plasmid replication in mycobacteria, thus suggesting that the Bglll site is in proximity to, or within a sequence necessary for mycobacteria plasmid replication.
4. Construction of pMV200 series vectors.
T acilitate manipulations of all the components necessary for plasmid replication in E. coli and mycobacteria, (E. rep. and
M. rep.) and selection of recombinants (KanR), cassettes of each component were constructed for simplified assembly in future vectors and to include a multiple cloning site (MCS) containing unique restriction sites and transcription and translation terminators. The cassettes were constructed to allow directional cloning and assembly into a plasmid where all transcription is unidirectional.
KanR Cassette
A DNA cassette containing the aph (KanR) gene was
constructed by PCR with primers Kan5' and Kan3'. An Spel site was added to the 5' end of the PCR primer Kan3', resulting in th formation of a PCR primer having the following sequence:
CTC GAC TAG TGA GGT CTG CCT CGT GAA G. 10
Bam HI + Nhel sites were added to the 5' end of the primer Kan5', resulting in the formation of a PCR primer having the following sequence:
CAG AGG ATC CTT AGC TAG CCA CT GAC GTC GGG G. 11
PCR was performed at bases 3375 and 4585 of pMV123, and BamHI and Nhel sites were added at base 3159, and an Spel site was added at base 4585. Digestion with BamHI and Spel, followed by purification resulted in a 1228/2443 KanR cassette bounded by BamHI and Spel cohesive ends with the direction of transcription for the aph gene proceeding from BamHI to Spe I.
E. rep. cassette
A DNA cassette containing the ColEI replicon of pUC19 was constructed by PCR with primers E.rep/Spe and E.rep/Mlu. An Spe site was added to the 5' end of PCR primer E.rep/Spe and an Mlul site was added to the 5' end of PCR primer E.rep./Mlu. The resulting primers had the following se-quences:
E. rep. /Spe
CCA CTA GTT CCA CTG AGC GTC AGA CCC 12
E. rep. p/Mlu
GAC AAC GCG TTG CGC TCG GTC GTT CGG CTG. 13
PCR was performed at bases 713 and 1500 of pUC19, and an Mlul site was added to base 713, and a Spel site was added to base 1500. Digestion with Mlul and Spel, followed by
purification resulted in an E.rep. cassette bounded by Spel and Mlul cohesive ends with the direction of transcription for RNA I and RNA II replication primers proceeding from Spel to Mlul.
M.rep. cassette
A DNA cassette containing sequences necessary for plasmid replication in mycobacteria was constructed by PCR of pMV123 with primers M.rep/Mlu and M. rep/Bam. An Mlul site was added to the 5' end of PCR primer M.rep/Mlu. A BamHI site was added to the 5' end of PCR primer M. rep/Bam. The resulting PCR primers had the following base sequences:
M.rep.p/Mlu
CCA TAC GCG TGA GCC CAC CAG CTC CG 14
M.rep. /Bam
CAC CCG TCC TGT GGA TCC TCT AC 15
PCR was performed at bases 134 and 2082 of pMV123. An Mlul sited was added to base 2082. Digestion with BamHI and Mlul, followed by gal purification resulted in a 1935 base pair DNA cassette bounded by Mlul and BamHI cohesive ends with the
direction of transcription for the pAL5000 ORFl and ORF2 genes proceeding from Mlul to Bam HI.
The KanR, E.rep, and M.rep PCR cassettes were then mixed in equimolar concentrations and ligated, and then transformed in E.
coli strain HB101 for selection of KanR transformants. Colonies were screened for the presence of plasmids carrying all three cassettes after digestion with BamHI + Mlul + Spel and designated pMV200. A additional restriction site, Ncol, was eliminated from the M. rep cassette by digestion of pMV200 with Ncol, fill in with Klenow, and ligation and recircularization, resulting in the formation of pMV201. A schematic of the formation of pMV200 from pMV123 and pUC19, and of pMV201 from pMV200, is shown in Figure 11. Plasmids pMV200 and pMV201 were transformed into M.
smegmatis and BCG. Both plasmids yielded KanR transformants, thus indicating their ability to replicate in mycobacteria.
A synthetic multiple cloning sequence (MCS) (Figure 12) was then designed and synthesized to facilitate versatile molecular cloning and manipulations for foreign gene expressions in
mycobacteria, and for integration into the mycobacterial
chromosome. The synthetic MCS, shown in Figure 12, contains 16 restriction sites unique to pMV201 and includes a region carrying translation stop codons in each of three reading frames, and a transcription terminator derived from E. coli 5S ribosomal RNA (Tl).
To insert the MCS cassette, pMV201 was digested with Narl and Nhel, and the resulting fragment was gel purified. The MCS was digested with HinPI and Nhel and, the resulting fragment was gel purified. The two fragments were then ligated to yield pMV204. A schematic of the construction of pMV204 is shown in Figure 13.
Plasmid pMV204 was then further manipulated to facilitate removal of the M.rep cassette in further constructions. pMV204 was digested with Mlul, and an Mlul - Not I linker was inserted into the MluI site between the M. rep and the E.rep to generate pMV206. A schematic of the construction of pMV206 from pMV204 is shown in Figure 14, and the DNA sequence of pMV206 is given in Figure 15.
5. Construction of expression cassette based on BCG HSP60.
The HSP61 cassette (Figure 6) was constructed as hereinabove described in Example 1.
Each of pMV206 and the PCR cassette HSP61 was digested with XbaI and BamHI . The PCR cassette was then inserted between the XbaI and BamHI sites of pMV206, then ligated to form plasmid pMV261. The construction of this plasmid is shown schematically in F ure 17. The reading frame and the restriction sites of the multiple cloning site of pMV261 is shown in Figure 16.
The E. coli lac Z gene was used as a reporter, or marker gene to assay the ability of the HSP61 cassette to express heterologous genes in BCG. A BamHI restriction fragment carrying the lac Z gene was cloned into the Bam HI site of Bam HI digested pMV261, resulting in the formation of pMV261/LZ. A schematic of the construction of pMV261/LZ is shown in Figure 18. The
formation of pMV261/LZ results in a fusion between the HSP60 and lac Z genes at the sixth codon of the HSP60 gene and the sixth . codon of the lac Z gene. pMV261/LZ was then transformed into E. coli. Blue E. coli colonies were selected on x-gal plates for the presence of pMV261/LZ, thus indicating that the HSP60
promoter and translation initiation sequences were also active in E. coli.
pMV261/LZ was then transformed into BCG and plated on Dubos Oleic Agar plates containing x-gal. All BCG colonies resulting from this transformation exhibited blue color, thus indicating that the lac Z gene product (B-galactosidase) was expressed in BCG. SDS polyacrylamide gel electrophoresis was performed on lysates of the pMV261/LZ BCG recobinants, revealing that
B-galactosidase protein was expressed to levels in excess of 10% of total BCG protein (as determined by staining with Coomassie brilliant blue). These data indicated that BCG HSP61 expression cassette was functional in expression vector pMV261.
Plasmid pMV261/LZ was then shown to replicate autonomously, and express the E. coli B-galactosidase, or lacZ gene, driven by the BCG promoter HSP60, in M. smegmatis and BCG.
6. Transfer of mycobacteriophage L5 integration sequences to BCG expression vector.
Plasmid pMH9.4, which includes the mycobacteriophage L5 attP site, and the L5 integrase gene, was employed in providing the L5 integration sequences to a BCG expression vector. The
construction of pMH9.4, as well as its integration into M.
smegmatis and BCG, is described below in sections (i) through (vi).
(i) Identification of the DNA sequences of the attachment sites, attB, attL, and attR, of M. smegmatis.
Using standard technologies, a lambda EMBL3 library was constructed using chromosomal DNA prepared from mc 61 (a strain of M. smegmatis which includes an M. smegmatis chromosome into which has been integrated the genome of mycobacterial phage L5) and digested with Bam HI. Phage L5 contains DNA having restriction sites identical to those of phage L1 (Snapper, et al. 1988), except that L5 is able to replicate at 42°C and phage L1 is incapable of such growth. This library was then probed with 6.7 kb DNA fragment isolated from the L5 genome that had been previously identified as carrying the attP sequence (Snapper, et al 1988). One of the positive clones was plaque purified, DNA prepared, and a 1.1 kb Sal I fragment (containing the AttL sequence) sub-cloned into sequencing vector pUC119. The DNA sequence of this fragment was determined using a shotgun approach coupled with Sangβr sequencing. By isolating and sequencing the attL junction site and comparing this to the DNA sequence of L5 that was available, a region was determined where the two sequences aligned but with a specific discontinuity present. The discontinuity represents one side of a core sequence, which is identical in AttP, attB, and attL. The region containing the recombinational crossover point is shown in Figure 19.
The attL DNA (1.1 kb Sal I fragment) was used as a probe to hybridize to a Southern blot of Bam HI digested mc 6 DNA, which
is a strain of M. smegmatis which includes an M. smegmatis chromosome without any phage integration (Jacobs, et al, 1987, hereinabove cited.). A single band of approximately 6.4 kb was detected corresponding to the attB sequence of M. smegmatis. This same attL probe was used to screen a cosmid library of mc26 (provided by Dr. Bill Jacobs of the Albert Einstein College of Medicine of Yeshiva University), and a number of positive cosmid clones were identified. DNA was prepared from these clones, and a 1.9 kb Sal I fragment (containing the attB site) that hybridizes to the attL probe was subcloned into pUC119 for sequencing and further analysis. The DNA sequence containing the core sequence was determined and is shown in Figure 19. The core sequence, which is identical in attP, attB and attL, has a length of 43bp.
The mc261 lambda EMBL3 library was then probed with the
1.9kb Sail fragment containing the attB site. Positive plaques were identified, DNA was prepared, and analyzed by restriction analysis and Southern blots. Lambda clones were identified that contained a 3.2kb Bam HI fragment containing the putative attR site. The 3.2kb Bam HI fragment was purified and cloned into pUC119 for sequencing and further analysis.
(ii) Determination of attP-integrase region of L5 genome.
Concurrent with the above procedures, a significant portion of the DNA sequence of L5 had been determined and represented in several "contigs" or islands of DNA sequence. Sequences of the 6.7kb Bam HI fragment hereinabove described were determined by (a) analysis of the location of Bam HI sites in the contigs of the DNA of L5, and (b) by determining a short stretch of DNA sequence from around the Bam HI sites of plasmid pJR-1 (Figure 24), which carries the 6.7kb Bam HI fragment of L5.
A segment of DNA sequence was located that represented the 6.7kb Bam HI fragment of phage L5. Studies of other phages have shown that the integrase genes are often located close to the attP site. It was thus determined that the L5 integrase (int)
gene should lie either within the 6.7kb Bam HI fragment or in a DNA sequence on either side of it. The DNA sequence in the regions was then analyzed by translating it into all six possible reading frames and searching these amino acid sequences for similarity to the family of integrase related proteins, and through computer-assisted analysis of the DNA sequence. As shown in F r 20, there are shown two domains of reasonably good conservat n among L5 integrase and other integrases, and three amino acid residues that are absolutely conserved in domain 2. (See Yagil, et al., J. Mol. Biol.. Vol. 207, pgs. 695-717 (1989), and Poyart-Salmeron, et al., J . EMBO., Vol. 8, pgs. 2425-2433 (1989)). A region was identified, and analysis of the corresponding DNA sequence showed a reading frame that could encode for a protein of approximately 333 amino acids. These observations identified the putative int gene.
The location of the int gene was not within the 6.7kb Bam HI fragment; however, it was very close to it with one of the Bam HI sites (that defines the 6.7kb Bam HI fragment) less than 100 bp upstream of the start of the gene. Analysis of the Bam HI sites showed that the int gene lay within a 1.9kb Bam HI fragment located adjacent to the 6.7kb Bam HI fragment. This 1.9kb Bam HI fragment was cloned by purification of the fragment from a Bam HI digest of L5 DNA and cloning into pUC 119, to generate pMHl (Figure 25).
From a combination of the above approaches, a schematic of the organization of the attP-int region of L5 was constructed (Figure 26), and the gene sequence of the attP-int region is given in Figure 22.
(iii) Construction of pMH5.
The 6.7kb Bam HI fragment of mycobacteriophage L5, which contains the attP site, as hereinabove described, was cloned into the Bam HI site of pUC 119 (Figure 23). This was achieved by purifying the 6.7kb Bam HI fragment from a Bam HI digest of L5
DNA separated by agarose gel electrophoresis and ligating with Bam HI cut pUC 119. DNA was prepared from candidate recombinants and characterized by restriction enzyme analysis and gel electrophoresis. A recombinant was identified that contained the 6.7kb Bam HI fragment of L5 cloned into pUC 119. This plasmid was named pJR-1, as shown in Figure 24.
lysis of DNA sequence data from a project to sequence L5 showed that a 1.9kb Bam HI fragment adjacent to the 6.7kb Bam HI fragment hereinabove described contained the integrase gene.
A plasmid containing a 1.9kb Bam HI fragment containing the DNA encoding for the integrase cloned into the Bam HI site of pUC 119 was constructed. The 1.9kb fragment was purified from a Bam HI digest of L5 DNA and cloned into the Bam HI site of pUC 119. Construction of the recombinant was determined by restriction analysis and gel electrophoresis. This plasmid was called pMHI, the construction of which is shown schematically in Figure 25. pJR-1 was then modified by digestion with EcoRI and SnaBI (both are uni«que cloning sites), between which is a Bam HI site. The EcoRI-SnaBI fragment, including the Bam HI site was excised, and the. plasmid was religated to form plasmid of pMH2, which contains on Bam HI site compared to two Bam HI sites contained in pJR-1. A schematic of the construction of pMH2 is shown in Figure 26.
The 1.9kb Bam HI fragment, which includes the integrase gene, was purified from a Bam HI digest of pMHl and ligated to Bam HI digested pMH2. Recombinants were identified as above and the orientation of the 1.9kb fragment determined. A plasmid called pMH4 was thus constructed (Figure 27) in which the region from the Sna BI site (upstream of attP) through to the Bam HI site (downstream of the integrase gene) was identical to that in
L5.
pMH4 was digested with HindiII (unique site) and was ligated to a lkb Hindlll fragment purified from pKD43 (supplied by Keith Derbyshire of the Nigel Gindley Laboratory) that contains the
gene determin ig resistance to kanamycin Recombinants were identified and characterized as above. This plasmid is called pMH5. A schematic of the construction of pMH5 is shown in Figure 28.
(iv) Integration of PMH5 into attB of M. smegmatis.
Plasmids pYUB12 (a gift from Dr. Bill Jacobs, a schematic of the formation of which is shown in Figure 1), pMDOl (Figure 29), and pMH5 were electroporated, with four different concentration of plasmid DNA over a 1,000-fold range, into M. smegmatis strai mc2155, a strain which is able to support plasmid replication.
In sections (iv) through (vi), all electroporation procedures of
M. smegmatis, or of BCG, were carried out as follows:
Cultures of organism were grown in Middlebrook 7H9 media, as described by Snapper, et al. (1988), harvested by centrifugation, washed three times with cold 10% glycerol, and resuspended at approximately a 100 × concentration of cells.
1 μl of DNA was added to 100 μl of cells in an ice-cold cuvette and pulsed in a Bio-Rad Gene Pulser, and given a single pulse at 1.25 kv at 25 μF. 1 ml of broth was added the cells incubated for 1 hr. at 37°C for expression of the antibiotic-resistant marker. Cells were then concentrated and plated out on Middlebrook or tryptic soy media containing 15 μg/ml kanamycin. Colonies were observed after 3 to 5 days incubation at 37°C.
Each of pYUB12, pMD01, and pMH5 carries kanamycin resistance. Plasmid pYUB12 carries an origin of DNA replication, while pMDOl lacks a mycobacterial origin of replication. Plasmid pMH5 does not carry a mycobacterial origin of replication, but carries a 2kb region of phage L5 which contains the attP site and the integrase gene (Figure 22). The number of transformants were linear with DNA concentration. Plasmid pYUB12 gives a large number of transformants (2 × 10 5 per μg DNA) in mc2155, while pMH5 gives 6 × 104 transformants per μg DNA, and pMDOl gives no transformants .
The above experiment was then repeated by electroporating the plasmids pYUB12, pMD01, and pMH5 into M. smegmatis strain mc 6, which does not support plasmid replication. No transformants in mc 6 were obtained from pYUB12 or pMD01 while pMH5 gave approximately 10 kanamycin resistant transformants in mc 6 per μg of DNA, thus indicating integration of pMH5 into the mc 6 chromosome.
DNA from six independent pMH5 transformants (four in mc2 155 and two in mc26) was prepared. These DNA's (along with DNA from both mc2155 itself, and mc 155 carrying the plasmid pYUB12) were digested with a restriction enzyme, and analyzed by Southern blot and hybridization with the M. smeqmatis 1.9kb attB probe hereinabove described. As shown in Figure 30, all six transformants have integrated into the attB site, resulting in the production of two new DNA fragments with different mobilities. If pMH5 did not integrate into the attB site, it would be expected that a single band, corresponding to the attB site in the mc2155 control, would be obtained.
(v) Construction of pMH9.2 and pMH9.4
pUC119 was digested with Hindlll, and a 1kb HindIII fragment, containing a kanamycin resistance gene, purified from pKD43, was ligated to the HindIII digested pUC119 to form pMH8
(Figure 31). A 2kb Sail fragment (bp 3226-5310), which carries the attP and integrase gene from Sail digested pMH5, was purified and inserted in both orientations relative to the vector backbone of Sail digested pMH8 to form plasmids pMH9.2 and pMH9.4 (Figures
32 and 33).
M. smegmatis strain mc2155 cells carrying, as a result of electroporation, plasmid pYUB12, pMH9.2 or pMH9.4, or strain mc26 cells carrying plasmid pMH5, as a result of electroporation as hereinabove described, were grown to saturation in broth with kananmycin. Cultures were then diluted 1:100 into broth without kanamycin and grown to saturation. Two further cycles of dilution and growth were done, corresponding to about 20
generations of bacterial growth. Cultures were plated out to single colonies on non-selective plates, and approximately 100 of these colonies were patch plated onto both non-selective and selective plates. The % of colonies that were sensitive to kanamycin, thus corresponding to the percentage of cells which lost the plasmid, is given below in Table I.
Table I
% loss
pYUB12 (mc2155) 35
pMH5 (mc26) 17
PMH9.2 (mc2155) 3
PMH9.4 (mc2155) 0
(vi) Transformation of BCG with pMH9.4
The 1.9 kb Sal I fragment, which includes the M. smegmatis attB site as hereinabove described was cloned into pUC119, and the plasmid generated was named pMH-12. (Figure 34).
Gel purified Sal I 1.9kb M. smegmatis fragment containing attB (isolated from pMH-12) was used to probe a Southern transfer of Bam HI digested mycobacterial DNA's, including BCG substrain Pasteur, shown in Figure 35. This demonstrated that there is one Bam HI fragment of BCG that strongly hybridizes to the M. smegmatis attB probe and three hybridize weakly. The strongest hybridizing band is the fastest moving band (approximately 1.9 kb).
The same probe as above was used to probe a BCG cosmid library (provided by Dr. Bill Jacobs) and positive clones were identified. DNA was prepared from several positive clones and analyzed by restriction analysis and Southern blotting. The 1.9 kb Bam HI fragment (corresponding to the strongly hybridizing band in the Southern blot was identified, gel purified from the cosmid DNA and cloned into pUC119. The resulting plasmid was named pMH-15. (Figure 36).
Plasmid pMH-5 and pMH9.4 were electroporated into BCG Pasteur. It was observed that pMH9.4 transforms BCG with high
efficiency (approximately 104 transformants/μg DNA), while pMH-5 transforms BCG at low efficiency (1-10 transformants/μg DNA).
DNA was prepared from BCG transformants and analyzed by Bam HI restriction and Southern blot analysis, probing with gel purified
1.9kb Bam H BCG attB fragment from pMH-15. These data are shown in Figure 37 and show that integration of both pMH5 and pMH9.4 is specific to the BCG attB site (ie. the strongly cross-hybridizing fragment in BCG). This is illustrated by the loss of the 1.9kb
Bam HI fra«gment from the transformants and the appearance of two new bands representing attL and attR junction fragments. Figure
37 shows just one of the pMH5/BCG transformants, although all of the four that were analyzed show that one of the bands (the largest) is smaller than expected (and different in each of the transformants), indicating that the transformation effiency of pMH-5 is low in BCG. In contrast, the four pMH9.4 transformants are identical to each other (Figure 37) and give attR and attL junction fragments of the predicted sizes.
Plasmid pMH9.4, which includes the mycobacterial phage L5 attP site and the L5 integrase gene, was digested to completion with either Kpnl + PvuII or Xbal + PvuII, and a restriction fragment of 1862 or 1847 base pairs, respectively, each of which contain the attP site and the integrase gene, were purified by agarose gel electrophoresis. Plasmid pMV261/LZ was digested with
Xbal or DraI to generate either a 7569 bp or 7574 bp vector fragment. The 7569 bp fragment was ligated to the 1862 bp fragment derived from pMH9.4 to form pMV460/LZ. The 7574 bp fragment was ligated to the 1847 bp fragment derived from pMH9.4 to form pMV460 R/LZ. Plasmids pMV460 F/L2 and pMV460R/L2 each include a mycobacterial replicon, the L5 attP site, and the L5 integrase gene. A schematic of the formation of plasmids pMV460
F/LZ and pMV460R/LZ is shown in Figure 38. To generate derivatives without the mycobacterial plasmid replicon, plasmids pMV460/LZ and pMV460/LZ were digested with NotI and recircularized by ligation to generate pMV360F/LZ and pMV360R/LZ.
A schematic of the construction of pMV360F/LZ and pMV360R/LZ is shown in Figure 39.
Plasmids pMH9.4, pMV261/LZ, pMV460/LZ, pMV460/LZ, pMV460/LZ and pMV460/LZ were then transformed into M. smeqmatis and BCG to test their ability to replicate autonomously or integrate into the M. smegmatis or the BCG chromosome. Transformation with pMH9.4, pMV261/LZ, pMV360F/LZ, and pMV360R/LZ yielded kananmycin resistan transformants of M. smeqmatis and BCG. Transformants of pMV261LZ, pMV360F/LZ, and pMV360R/LZ were shown to express E. coli B-galactosidase by SDS-polyacrylamide gel electrophoresi and X-gal assay. Plasmids pMV460F/LZ and pMV460R/LZ failed to yield kanamycin resistant transformants, thus indicating that chromosomal integration of a plasmid carrying sequences mediating autonomous replication is lethal to mycobacteria.
7. Construction of pMV307.
Plasmid pMV206 was digested with NotI to remove the mycobacterial replicon. The resulting 2209 bp fragment, which includes the aph (KanR) gene, the E. coli replicon and the multiple cloning site, was ligated and recircularized to for pMV205, the construction of which is schematically depicted in
Figure 14.
PCR with primers Xbal-Att/Int and Nhel-Att/Int was the performed on a Sal I fragment from pMH9.4, which contains the attP site and the L5 integrase gene. The resulting cassette was then digested with Xbal and Nhel and a 1789 bp fragment was gel purified. pMV205 was then digested with Nhel, and the resulting fragment was ligated to the 1989 bp fragment obtained from pMH9.4 to form pMV307. A schematic of the construction of pMV307 is shown in Figure 40.
8. Construction of pMV261./HIV1-gp 120.
An Smal-Clal antigen gene fragment, or cassette, was constructed by PCR, and cloned between the Bam HI and ClaI restriction sites of pMV261 to form pMV261/HIV1-gp 120.
Plasmid pMV261/HIV1-gp 120 was transformed into BCG, and the presence of the corresponding antigen in BCG was verified by the appearance of immunoreactive protein bands in Western blot analysis of BCG recombinant lysates.
9. Construction of pMV361./HIV1-gp_12_0
The HIV1-gp 120 antigen gene expression cassette, which includes a promoter sequence and an HIVl-gp 120 gene sequence, was excised from the pMV261 derivatives with NotI and a second restriction enzyme site (Pvu II, Eco RI, Sal I, Cla I or Hind III) and cloned into the integrating plasmid pMV307 between the NotI site and a second enzyme site (Pvu II, Eco RI, Sal I, Cla I or Hind III) to form the plasmid pMV361/HIV-Igpl20. The backbone of this plasmid is shown in Figure 41.
Plasmid pMV361/HIV-Igp120 was transformed into BCG and shown to express the corresponding antigens by Western blot analysis (Figure 42) with the appropriate antigen-specific human sera.
Example 4
Cytotoxic T lymphocyte responses to HIV-1-gp 120
HIV-1 gp 120 was expressed in BCG as a six amino acid fusion protein with BCG hsp 60 protein using vector pMV361/HIV-1-gp120, using the hsp 60 promoter to control expression.
Two groups of mice were inoculated with 1 × 10 CFU's of recombinant BCG expressing the gp 120 gene from the integrative plasmid pMV361/HIV-1-gp120. One group received the BCG via intraperitonal injection (100 ul) whereas the other group received the BCG by deposition of the dose (10 ul) rubbed into a tail scratch.
CTL activity was measured at various times after immunization. CTL activity was measured as follows:
Two mice from each group were sacrificed at various times after immunation, and the spleens were removed. Single cell suspensions were made and the red blood cells were lyzed with ammonium chloride. The cells were stimulated in vitro for 5 days with P815 cells- that were pulsed with peptide P18, a fifteen
residue synthetic peptide within HIV1-gp 120. A 4-hour chromium (Cr 51 ) release assay was then carried out using untreated P815 and peptide P18 pulsed P815 cells as targets. Significant
P18-specific CTL activity was observed in the mice immunized by tail scratch 14 weeks after immunization. At 16 weeks, CTL activity was observed in both groups of mice. Upon repeat of this experiement, CTL activity was observed at time points as early as 8 weeks after immunization.
Example 5
Recombinant BCG transformed with pMV361/HIV1-gp 120 were grown to mid-log phase in Dubos media and concentrated by centrifugation. The bacteria were then resuspended in 15% glycerol and frozen using a rate contolled freezing apparatus.
The bacteria were stored at -70°C until use (referred to as
"vaccine"). A second preparation grown in the same way was not frozen and is referred to as a "fresh" preparation. Prior to immunization of animals, the bacteria were resuspended in PBS +
0.05% Tween 80 to the desired concentration and cup sonicated briefly to disperse clumped bacteria. Six week old BALB/c mice were inoculated with a single dose of 5 × 10 4 cfu fresh bacteria
(determined post inoculation) or 1.5 × 10 frozen bacteria
(determined pre-inoculation) by tail scratch (t.s.) injection.
At 8 weeks post-immunization, splenocytes were harvested from animals and CTL activity was measured (described below).
Splenocytes from unimmunized animals were used as controls in the
CTL assays.
CTL activity was determined as follows:
Splenocytes (ACK-treated, 5 × 10 /ml) were stimulated in vitro in 10 ml in upright T25 flasks by co-culture for 5 days with mitomycin C-treated P815 cells (5 × 10 /ml) that were pulsed with 250 ug/ml of peptide P18 for one hour. A 4 hr. 51Cr release assay was subsequently performed in triplicate using P815 targets with or without pulsing for 1 hour with 250 ug/ml peptide P18.
Various effector-target ratios were tested using 5000
targets/well. Specific lysis was calculated as follows: % specific lysis = 100 × [release by effector cells minus spontaneous release/maximal release minus spontaneious release].
The results are given in Figure 42.
As shown in Figure 43, both groups of mice showed an increased CTL response at 8 weeks after immunization as compared with unimmunized mice.
Example 6
Recombinant BCG transformed with pMV361/HIVl-gp 120. were grown to mid-log phase in Dubos media and concentrated by centrifugation. The bacteria were then resuspended in 15% glycerol and frozen using a rate contolled freezing apparatus.
The bacteria were stored at -70°C until use (referred to as
"vaccine"). A second preparation grown in the same way was not frozen and is referred to as a "fresh" preparation. Prior to immunization of animals, the bacteria were resuspended in PBS +
0.05% Tween 80 to the desired concentration and cup sonicated briefly to disperse clumped bacteria. Six week old BALB/c mice were inoculated with a single dose of 5 x 104 cfu fresh bacteria
(determined post inoculation) or 1.5 × 105 frozen bacteria
(determined pre-inoculation) by tail scratch (t.s.) injection.
At 8 weeks post-immunization, splenocytes were harvested from animals and CTL activity was measured (described below).
CTL activity was determined as follows:
Lymph node cells (5 × 10 /ml) were stimulated in vitro in 10 ml in upright T25 flasks by co-culture for 5 days with mitomycin
C-treated P815 cells (5 × 10 /ml) that were pulsed with 250 ug/ml of peptide P18 for one hour. A 4 hr Cr release assay was subsequently performed in triplicate using P815 (matched ) or EL4
(mismatched) targets with or without pulsing for 1 hour with 250 ug/ml peptide P18. Various effector target ratios were tested using 5000 targets/well. Specific lysis was calculated as follows: % specific lysis = 100 × [release by effector cells
minus spontaneous release/maximal release minus spontaneous release].
The results of this assay are given in Figure 44.
As shown in Figure 44, a CTL response to HIV-1 gp 120 using lymph node cells was demonstrated following immunization of mice with BCG transformed with pMV361/HIV-1 gp 120.
It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.
Claims (8)
1. A method of inducing a CTL response in an animal comprising:
administering to an animal mycobacteria transformed with at least one DNA sequence which encodes a protein or peptide or fragment or derivative thereof which includes an epitope which is recognized by cytotoxic T lymphocytes, said mycobacteria being administered in an amount effective to induce a CTL response in an animal.
2. The method of Claim 1 wherein said protein or peptide or fragment or derivative thereof includes an epitope which is recognized by cytotoxic T lymphocytes induced by an HIV protein or fragment or derivative thereof.
3. The method of Claim 2 wherein said protein or peptide or fragment or derivative thereof is an HIV protein or fragment or derivative thereof.
4. The method of Claim 1 wherein the mycobacteria are of the species M.bovis-BCG.
5. A composition for inducing a CTL response in an animal, comprising:
mycobacteria transformed with at least one DNA sequence which encodes a protein or peptide or fragment or derivative thereof which includes an epitope which is reocognized by cytotoxic T lymphocytes, and an acceptable pharmaceutical carrier, said mycobacteria being present in an amount effective to induce a CTL response in an animal.
6. The composition of Claim 5 wherein said protein or peptide or fragment or derivative thereof includes an epitope which is recognized by cytotoxic T lymphocytes induced by an HIV protein or fragment or derivative thereof.
7. The composition of Claim 6 wherein said protein or peptide or fragment or derivative thereof is an HIV protein or fragment or derivative thereof.
8. The composition of Claim 5 wherein said mycobacteria are of the species M.bovis-BCG.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71164391A | 1991-06-06 | 1991-06-06 | |
| US711643 | 1991-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2185592A true AU2185592A (en) | 1993-01-08 |
Family
ID=24858927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU21855/92A Abandoned AU2185592A (en) | 1991-06-06 | 1992-06-01 | Induction of ctl responses to foreign antigens expressed in mycobacteria |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0587775A4 (en) |
| AU (1) | AU2185592A (en) |
| CA (1) | CA2110682A1 (en) |
| WO (1) | WO1992021376A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08505625A (en) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | Induction of cytotoxic T lymphocyte response |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| EP0771322B9 (en) | 1993-11-23 | 2009-08-12 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| GB9426153D0 (en) * | 1994-12-23 | 1995-02-22 | Medical Res Council | Improvements in or relating to vaccines |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| US6693087B1 (en) | 1998-08-20 | 2004-02-17 | Aventis Pasteur Limited | Nucleic acid molecules encoding POMP91A protein of Chlamydia |
| CA2340330A1 (en) | 1998-08-20 | 2000-03-02 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein c of chlamydia |
| US6686339B1 (en) | 1998-08-20 | 2004-02-03 | Aventis Pasteur Limited | Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia |
| JP2003512829A (en) | 1999-10-22 | 2003-04-08 | アヴェンティス パストゥール リミテッド | Modified GP100 and uses thereof |
| EP1792995A3 (en) | 2000-05-08 | 2007-06-13 | Sanofi Pasteur Limited | Chlamydia secretory locus orf and uses thereof |
| EP1741782B1 (en) | 2000-05-10 | 2011-06-22 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
| ATE357461T1 (en) | 2000-08-25 | 2007-04-15 | Aventis Pasteur | INNER-CORE OLIGOSACCHARIDE EPITOPES FROM LIPOPOLYSACCHARIDES OF HAEMOPHILUS INFLUENZA AS VACCINES IN THE PROPHYLACTIC TREATMENT OF HAEMOPHILUS INFLUENZAE INFECTIONS |
| US7060462B2 (en) | 2000-11-02 | 2006-06-13 | National University Of Singapore | AopB gene, protein,homologs, fragments and variants thereof, and their use for cell surface display |
| WO2003050268A2 (en) | 2001-12-12 | 2003-06-19 | Aventis Pasteur Limited | Enhancement of the immune response using cd36-binding domain |
| PT1496939E (en) | 2002-04-09 | 2007-11-22 | Sanofi Pasteur Ltd | Modified cea nucleic acid and expression vectors |
| CN106008679A (en) | 2008-12-24 | 2016-10-12 | 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 | Modified Steptococcus pneumonia pneumolysin (PLY) polypeptides |
| WO2012101509A2 (en) | 2011-01-28 | 2012-08-02 | Sanofi Pasteur Sa | Immunological compositions against hiv |
| ES2575981T3 (en) * | 2011-04-18 | 2016-07-04 | Myongji University Industry And Academia Cooperation Foundation | Cyclic peptide derived from Nonomuraea sp., Process for its production, and pharmaceutical composition for the prevention or treatment of a disease related to mycobacteria comprising the same |
| AU2012294454B2 (en) | 2011-08-08 | 2017-02-02 | Curelab Oncology, Inc. | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer |
| US9303071B2 (en) | 2012-09-17 | 2016-04-05 | Novartis Tiergesundheit Ag | Salmonid alphavirus and uses thereof |
| US9809863B2 (en) | 2012-11-02 | 2017-11-07 | Elanco Tiergesundheit Ag | Flavivirus associated with Theiler's disease |
| WO2014140938A2 (en) | 2013-03-14 | 2014-09-18 | Centre Hospitalier Universitaire Vaudois | Immunological methods |
| SG11201605316VA (en) | 2013-12-29 | 2016-07-28 | Curelab Oncology Inc | Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases |
| PL3177644T3 (en) | 2014-08-05 | 2021-06-14 | MabQuest SA | Immunological reagents binding to pd-1 |
| US10730933B2 (en) | 2015-12-05 | 2020-08-04 | Centre Hospitalier Universitaire Vaudois | HIV binding agents |
| WO2017125815A2 (en) | 2016-01-22 | 2017-07-27 | MabQuest SA | Immunological reagents |
| WO2020012435A1 (en) | 2018-07-13 | 2020-01-16 | Lausanne University Hospital | Hiv binding agents |
| JP2022541900A (en) | 2019-07-15 | 2022-09-28 | ローザンヌ ユニヴァーシティ ホスピタル | HIV binding agent |
| TW202206098A (en) | 2020-08-11 | 2022-02-16 | 美商碩騰服務公司 | Anti-coronavirus vaccines |
| CN114315985A (en) | 2020-09-29 | 2022-04-12 | 硕腾服务有限责任公司 | Attenuated porcine epidemic diarrhea virus |
| CA3230802A1 (en) | 2021-08-31 | 2023-03-09 | Zoetis Services Llc | Attenuated alphavirus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| EP0681026A1 (en) * | 1987-03-02 | 1995-11-08 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
-
1992
- 1992-06-01 AU AU21855/92A patent/AU2185592A/en not_active Abandoned
- 1992-06-01 CA CA002110682A patent/CA2110682A1/en not_active Abandoned
- 1992-06-01 EP EP9292913615A patent/EP0587775A4/en not_active Withdrawn
- 1992-06-01 WO PCT/US1992/004538 patent/WO1992021376A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0587775A1 (en) | 1994-03-23 |
| EP0587775A4 (en) | 1994-11-02 |
| WO1992021376A1 (en) | 1992-12-10 |
| CA2110682A1 (en) | 1992-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2185592A (en) | Induction of ctl responses to foreign antigens expressed in mycobacteria | |
| US5583038A (en) | Bacterial expression vectors containing DNA encoding secretion signals of lipoproteins | |
| US6833135B1 (en) | DNA integration into “Mycobacterium spp.” genome by trans-complementation using a site-specific integration system | |
| EP0347425B1 (en) | Recombinant mycobacterial vaccine | |
| JP3485916B2 (en) | Expression vehicles for recombinant mycobacteria and uses thereof | |
| EP0792358A2 (en) | A polynucleotide tuberculosis vaccine | |
| EP0544685A1 (en) | Mycobacterial expression vector | |
| US6752994B2 (en) | Insertional mutations in mycobacteria | |
| US5866403A (en) | Homologously recombinant slow growing mycobacteria and uses therefor | |
| US5830457A (en) | Recombinant beta-lactamase, usable as carrier molecule in immunogenic compositions | |
| WO1992001783A1 (en) | Dna capable of site-specific integration into mycobacteria | |
| EP0972839A1 (en) | Insertional mutations in mycobacteria | |
| US5736367A (en) | Vectors and prokaryotes which autocatalytically delete antibiotic resistance | |
| US5968815A (en) | Promoter of M. paratuberculosis and its use for the expression of immunogenic sequences | |
| US6248581B1 (en) | Mycobacteria functional screening and/or expression vectors | |
| WO1994014318A1 (en) | Method of protection against streptococcus pneumoniae with transformed mycobacteria | |
| WO1992021374A1 (en) | Induction of immune response against tetanus toxin through administration of mycobacteria expressing tetanus toxin or fragments | |
| WO1993019603A1 (en) | Prokaryotes including dna encoding bacteriophage immunity | |
| WO1995032277A9 (en) | Insertional mutations in mycobacteria | |
| CA2205175C (en) | A polynucleotide tuberculosis vaccine | |
| WO1995032277A1 (en) | Insertional mutations in mycobacteria |